Baird lowered the firm’s price target on Zimmer Biomet to $145 from $155 and keeps an Outperform rating on the shares. The firm said they continue to execute well on a global basis and that broadening efforts in enabling technologies remain an under-appreciated part of this story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet to acquire OrthoGrid Systems, terms undisclosed
- Zimmer Biomet backs FY24 adjusted EPS view $8.00-$8.15, consensus $8.09
- Zimmer Biomet reports Q2 EPS $2.01, consensus $1.99
- Zimmer Biomet Signs Definitive Agreement to Acquire OrthoGrid Systems, Inc.
- Zimmer Biomet Announces Second Quarter 2024 Financial Results